Saniya Mahendiratta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saniya Mahendiratta has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Bikash Medhi
Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
4 shared publications - Phulen Sarma
Department of Pharmacology, All India Institute of Medical Sciences, Guwahati, Assam, India
4 shared publications - Subodh Kumar
Postgraduate Institute of Medical Education and Research (PGIMER). Chandigarh, India
4 shared publications - Ajay Prakash
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3 shared publications - Hardeep Kaur
Department of Pharmacology, PGIMER, Chandigarh, India
3 shared publications - Harpinder Kaur
Department of Pharmacology, PGIMER, Chandigarh, India
3 shared publications
Latest Publications
- Open Access
- 1 May 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 137, 111300
Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
- 1 May 2021
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 137, 111300
Open AccessStem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review
- 11 July 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e13990
Premature graying of hair: Risk factors, co‐morbid conditions, pharmacotherapy and reversal—A systematic review and meta‐analysis
Premature graying of hair (PGH) being a very common entity for which pharmacotherapy and reversibility are not properly addressed. Therefore, this systematic review was conducted to address these issues. For this relevant study were selected from various databases including PubMed, EMBASE, OVID, Web of science, Scopus and Google Scholar till January 20, 2019. Studies which reported risk factors, co‐morbid conditions associated with PGH, its pharmacotherapy and reversal were included in the study. Although many risk factors are reported in literature, smoking, vitamin deficiency (B12, folic acid and B7), mineral deficiency (low serum calcium and serum ferritin) are found to be associated with PGH. Other important risk factors are family history of PGH, obesity, high B.P, lack of exercise, drugs, genetic syndromes, dyslipidemia, thyroid disorders, hyperuricemia and alteration in liver function. PGH is found to be an important marker of CAD, more so in case of smoker. Among different pharmacotherapeutic management options, low grade recommendation (2A) is given to calcium pantothenate, PABA, calcium pantothenate + PABA combination. Anu‐tailam is the only herbal agent evaluated in clinical research settings. Finally treating the accompanying pathologies led to the reversal of the disease in many cases.
- 11 July 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (6) , e13990
Premature graying of hair: Risk factors, co‐morbid conditions, pharmacotherapy and reversal—A systematic review and meta‐analysis
Premature graying of hair (PGH) being a very common entity for which pharmacotherapy and reversibility are not properly addressed. Therefore, this systematic review was conducted to address these issues. For this relevant study were selected from various databases including PubMed, EMBASE, OVID, Web of science, Scopus and Google Scholar till January 20, 2019. Studies which reported risk factors, co‐morbid conditions associated with PGH, its pharmacotherapy and reversal were included in the study. Although many risk factors are reported in literature, smoking, vitamin deficiency (B12, folic acid and B7), mineral deficiency (low serum calcium and serum ferritin) are found to be associated with PGH. Other important risk factors are family history of PGH, obesity, high B.P, lack of exercise, drugs, genetic syndromes, dyslipidemia, thyroid disorders, hyperuricemia and alteration in liver function. PGH is found to be an important marker of CAD, more so in case of smoker. Among different pharmacotherapeutic management options, low grade recommendation (2A) is given to calcium pantothenate, PABA, calcium pantothenate + PABA combination. Anu‐tailam is the only herbal agent evaluated in clinical research settings. Finally treating the accompanying pathologies led to the reversal of the disease in many cases.
- 12 November 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (1) , e13167
Therapeutic options for management of Hori's nevus: A systematic review
Introduction Hori's nevus is a pigmentation disorder reported mainly in middle‐aged Asian women. There is no systematic review addressing its pharmacotherapy. Materials and methods The population for our systematic review was patients with a clinical/ histological diagnosis of Hori's nevus (both sex, any age group). We screened 5 literature databases using relevant keywords. All RCTs, observational studies and case series mentioning at least one intervention and outcome of that intervention were included. Result 19 studies were included in the final systematic review from total 680 identified non‐duplicate records. Different forms of laser[alexandrite laser (QSAL and PSAL), Nd:YAG laser (QSNYL high fluence, low fluence, 532 followed by 1064 nm), Er: YAG and Nd:YAG combination, ruby laser (QSRL), CO2 laser followed by QSRL] and dermabrasion were found to be useful in treatment of Hori' nevus. Conclusion Among alexandrite lasers, PSAL is more efficacious and safe than QSAL.In case of high fluence QSNYL, hyperpigmentation rate is quite high while low fluence QSNYLrequires morenumber of treatment sessions. The combined 1064nm + 532 nm protocol is better in terms of efficacy and safety. Er:YAG + Nd:YAG combination have similar efficacy and added advantage of synergistic action and no adverse event.
- 12 November 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 33 (1) , e13167
Therapeutic options for management of Hori's nevus: A systematic review
Introduction Hori's nevus is a pigmentation disorder reported mainly in middle‐aged Asian women. There is no systematic review addressing its pharmacotherapy. Materials and methods The population for our systematic review was patients with a clinical/ histological diagnosis of Hori's nevus (both sex, any age group). We screened 5 literature databases using relevant keywords. All RCTs, observational studies and case series mentioning at least one intervention and outcome of that intervention were included. Result 19 studies were included in the final systematic review from total 680 identified non‐duplicate records. Different forms of laser[alexandrite laser (QSAL and PSAL), Nd:YAG laser (QSNYL high fluence, low fluence, 532 followed by 1064 nm), Er: YAG and Nd:YAG combination, ruby laser (QSRL), CO2 laser followed by QSRL] and dermabrasion were found to be useful in treatment of Hori' nevus. Conclusion Among alexandrite lasers, PSAL is more efficacious and safe than QSAL.In case of high fluence QSNYL, hyperpigmentation rate is quite high while low fluence QSNYLrequires morenumber of treatment sessions. The combined 1064nm + 532 nm protocol is better in terms of efficacy and safety. Er:YAG + Nd:YAG combination have similar efficacy and added advantage of synergistic action and no adverse event.